S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.
UAMS is a top accruing site for this national study comparing treatments for high-risk, early-stage non-small cell lung cancer (NSCLC). This study is testing whether stereotactic body radiotherapy (SBRT) plus the immune checkpoint inhibitor atezolizumab is better than the standard treatment of SBRT alone. Other trials have shown that a checkpoint inhibitor can benefit people with NSCLC. There is evidence that checkpoint inhibitors are safe and work well when given with radiation treatments. This study will further test this in people with medically inoperable, high-risk, early-stage non-small cell lung cancer.
Principal Investigator: Sanjay Maraboyina, M.D.